Canada markets closed

Pacific Edge Limited (PFGTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.06390.0000 (0.00%)
At close: 10:05AM EDT

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800
https://www.pacificedgedx.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees114

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter MeintjesChief Executive OfficerN/AN/AN/A
Mr. Grant GibsonChief Financial OfficerN/AN/AN/A
Mr. Darrell MorganChief Operating OfficerN/AN/AN/A
Dr. Justin HarveyChief Technology OfficerN/AN/AN/A
Prof. Parry Guilford Ph.D.Chief Scientific Officer & Member of Scientific Advisory Board80.49kN/AN/A
Mr. Jack AtchasonSenior Vice President of Sales - Pacific Edge Diagnostics USA LimitedN/AN/AN/A
Mr. Andrew McIntoshChief Digital OfficerN/AN/AN/A
Glen CostinPresident of Asia PacificN/AN/AN/A
Dr. Tamer AboushwarebChief Medical OfficerN/AN/AN/A
Mr. David LevisonExecutive Chairman & President of Pacific Edge Diagnostics USA31.83kN/A1960
Amounts are as of December 31, 2009 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Corporate Governance

Pacific Edge Limited’s ISS Governance QualityScore as of March 1, 2024 is 4. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.